Evidence map›Paper›PMID 34638322›Full record

ArticleCancers2021

Morphological Features Extracted by AI Associated with Spatial Transcriptomics in Prostate Cancer.

Eduard Chelebian, Christophe Avenel, Kimmo Kartasalo, Maja Marklund, Anna Tanoglidi, Tuomas Mirtti, Richard Colling, Andrew Erickson, Alastair D Lamb, Joakim Lundeberg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Novel insights from spatial transcriptome analysis in solid tumors.International journal of biological sciences · 2023
    Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Eduard ChelebianScience for Life Laboratory, Department of Information Technology, Uppsala University, 752 37 Uppsala, Sweden.ORCID 0000-0001-6852-6605
Christophe AvenelScience for Life Laboratory, Department of Information Technology, Uppsala University, 752 37 Uppsala, Sweden.ORCID 0000-0002-1835-921X
Kimmo KartasaloDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0002-9470-4783
Maja MarklundScience for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, 171 65 Solna, Sweden.ORCID 0000-0003-2627-2437
Anna TanoglidiDepartment of Clinical Pathology, Uppsala University Hospital, 752 37 Uppsala, Sweden.ORCID 0000-0002-1217-2219
Tuomas MirttiDepartment of Pathology, Research Program in Systems Oncology, University of Helsinki, Helsinki University Hospital, 00100 Helsinki, Finland.ORCID 0000-0003-0455-9891
Richard CollingNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-6344-9081
Andrew EricksonNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-4850-4086
Alastair D LambNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-2968-7155
Joakim LundebergScience for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, 171 65 Solna, Sweden.ORCID 0000-0003-4313-1601
Carolina WählbyScience for Life Laboratory, Department of Information Technology, Uppsala University, 752 37 Uppsala, Sweden.ORCID 0000-0002-4139-7003
University of Oxford · GBUppsala University · SEScience for Life Laboratory · SEKarolinska Institutet · SEUniversity of Helsinki · FIUppsala University Hospital · SE

Funding

Cancer Research UK 25812European Research Council ERC Consolidator grant CoG 68281
6 · The paper itself

Abstract

Prostate cancer is a common cancer type in men, yet some of its traits are still under-explored. One reason for this is high molecular and morphological heterogeneity. The purpose of this study was to develop a method to gain new insights into the connection between morphological changes and underlying molecular patterns. We used artificial intelligence (AI) to analyze the morphology of seven hematoxylin and eosin (H&E)-stained prostatectomy slides from a patient with multi-focal prostate cancer. We also paired the slides with spatially resolved expression for thousands of genes obtained by a novel spatial transcriptomics (ST) technique. As both spaces are highly dimensional, we focused on dimensionality reduction before seeking associations between them. Consequently, we extracted morphological features from H&E images using an ensemble of pre-trained convolutional neural networks and proposed a workflow for dimensionality reduction. To summarize the ST data into genetic profiles, we used a previously proposed factor analysis. We found that the regions were automatically defined, outlined by unsupervised clustering, associated with independent manual annotations, in some cases, finding further relevant subdivisions. The morphological patterns were also correlated with molecular profiles and could predict the spatial variation of individual genes. This novel approach enables flexible unsupervised studies relating morphological and genetic heterogeneity using AI to be carried out.

Indexed as

deep learningmorphological featuresprostate cancerspatial transcriptomics

Identifiers

PMID34638322
PMCPMC8507756
OpenAlexW3204251661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.